Eli Lilly halts bima diabetes combination trial, Laekna "named" and shares surge
```
On September 25, according to the U.S. clinical trial registry, Eli Lilly withdrew the Phase IIb clinical trial of ActRIIA/B monoclonal antibody bimagrumab in combination with the core component of semaglutide, tirzepatide, for the treatment of patients with type 2 diabetes, citing "strategic business reasons."
This